KURA (Kura Oncology, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by KURA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Brian T. Powl | Chief Commercial Officer | Sell | — | — |
| 2026-08-24 | TROY EDWARD WILSON | President and CEO | Buy | — | — |
| 2026-08-21 | Teresa Brophy Bair | Chief Legal Officer | Sell | — | — |
| 2026-08-17 | TROY EDWARD WILSON | President and CEO | Buy | — | — |
| 2026-06-22 | Mollie Leoni | Chief Medical Officer | Sell | — | — |
| 2026-06-04 | Diane L. Parks | Director | A | — | — |
| 2026-06-04 | Helen Louise Collins | Director | A | — | — |
| 2026-06-04 | Mary T Szela | Director | A | — | — |
| 2026-06-04 | CAROL SCHAFER | Director | A | — | — |
| 2026-06-04 | Faheem Hasnain | Director | A | — | — |
| 2026-06-04 | Thomas Malley | Director | A | — | — |
| 2026-06-04 | MICHAEL VASCONCELLES | Director | A | — | — |
| 2026-05-22 | Brian T. Powl | Chief Commercial Officer | Sell | — | — |
| 2026-05-20 | KATHLEEN FORD | Chief Operating Officer | Sell | — | — |
| 2026-05-20 | Brian T. Powl | Chief Commercial Officer | Sell | — | — |
| 2026-05-20 | Teresa Brophy Bair | Chief Legal Officer | Sell | — | — |
| 2026-03-25 | TROY EDWARD WILSON | President and CEO | M | — | — |
| 2026-03-20 | Thomas Malley | Director | M | — | — |
| 2026-01-27 | KATHLEEN FORD | Chief Operating Officer | Sell | — | — |
| 2026-01-27 | Mollie Leoni | Chief Medical Officer | Sell | — | — |
| 2026-01-27 | Brian T. Powl | Chief Commercial Officer | Sell | — | — |
| 2026-01-27 | Francis Burrows | Chief Scientific Officer | Sell | — | — |
| 2026-01-27 | Teresa Brophy Bair | Chief Legal Officer | Sell | — | — |
| 2026-01-27 | THOMAS JAMES DOYLE | SVP, Finance & Accounting | Sell | — | — |
| 2026-01-06 | Francis Burrows | Chief Scientific Officer | A | — | — |
| 2026-01-06 | KATHLEEN FORD | Chief Operating Officer | A | — | — |
| 2026-01-06 | Brian T. Powl | Chief Commercial Officer | A | — | — |
| 2026-01-06 | THOMAS JAMES DOYLE | SVP, Finance & Accounting | A | — | — |
| 2026-01-06 | Mollie Leoni | Chief Medical Officer | A | — | — |
| 2026-01-06 | TROY EDWARD WILSON | President and CEO | A | — | — |
| 2026-01-06 | Teresa Brophy Bair | Chief Legal Officer | A | — | — |
| 2025-12-19 | Francis Burrows | Chief Scientific Officer | MIXED | — | — |
| 2025-12-10 | Faheem Hasnain | Director | MIXED | — | — |
| 2025-11-14 | Brian T. Powl | Chief Commercial Officer | MIXED | — | — |
| 2025-11-14 | KATHLEEN FORD | Chief Operating Officer | MIXED | — | — |
| 2025-11-14 | TROY EDWARD WILSON | President and CEO | A | — | — |
| 2025-11-14 | Teresa Brophy Bair | Chief Legal Officer | MIXED | — | — |
| 2025-11-14 | THOMAS JAMES DOYLE | SVP, Finance & Accounting | MIXED | — | — |
| 2025-11-14 | Mollie Leoni | Chief Medical Officer | MIXED | — | — |
| 2025-09-29 | Mollie Leoni | Chief Medical Officer | MIXED | — | — |
| 2025-09-29 | Teresa Brophy Bair | Chief Legal Officer | MIXED | — | — |
| 2025-09-29 | Brian T. Powl | Chief Commercial Officer | MIXED | — | — |
| 2025-09-29 | TROY EDWARD WILSON | President and CEO | MIXED | — | — |
| 2025-09-29 | THOMAS JAMES DOYLE | SVP, Finance & Accounting | MIXED | — | — |
| 2025-09-29 | KATHLEEN FORD | Chief Operating Officer | MIXED | — | — |
| 2025-09-09 | TROY EDWARD WILSON | President & CEO | Buy | — | — |
| 2025-08-14 | TROY EDWARD WILSON | President and CEO | Buy | — | — |
| 2025-06-06 | MICHAEL VASCONCELLES | Director | A | — | — |
| 2025-06-06 | CAROL SCHAFER | Director | A | — | — |
| 2025-06-06 | Diane L. Parks | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,408,097 | — |
| — | President and CEO | 914,650 | — |
| — | Head of Development & CMO | 357,973 | — |
| — | Chief Legal Officer | 195,444 | — |
| — | Chief Medical Officer | 182,345 | — |
| — | Chief Commercial Officer | 169,269 | — |
| — | Chief Operating Officer | 153,560 | — |
| — | Director | 149,557 | — |
| — | SVP, Finance & Accounting | 146,548 | — |
| — | Chief Medical Officer | 46,400 | — |
| — | Chief Scientific Officer | 32,424 | — |
| — | Director | 23,983 | — |
| — | CFO, CBO | 21,900 | — |
| — | CCO & Chief Strategy Officer | 20,605 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KURA quote page; the site-wide leaderboard is on the insider transactions hub.